White paper

Insights from CGT launches

Navigating the complex commercialization journey with Cencora’s CGT team
team insights
team insights
What can manufacturers learn from 30+ approved CGTs? From launch planning and distribution to market access and growth, CGT team leaders Mark Kelley and Louis Cicchini share insights from supporting 200+ manufacturers. 
team insights

Article

Why early, big-picture planning is key to execution across the CGT lifecycle

For cell and gene therapies, the solution for the challenge you have today may create another challenge tomorrow. Early decisions around clinical development, manufacturing, regulatory strategy, and evidence generation can affect commercialization years later. See how successful manufacturers can take a cross-functional approach across the lifecycle to prevent obstacles before they occur. 

Connect with our cell and gene experts

Schedule some time with our cell and gene experts today. We look forward to hearing from you.
Abstract

Related resources

meeting

Article

Optimizing the channel strategy for your CGT: Considerations for a purpose-built approach
HTAQ abstract logo

Newsletter

HTA Quarterly Fall 2026

Article

The price patients pay: A peek into the financial burden for breast cancer patients diagnosed with mental health comorbidities